(Health-NewsWire.Net, May 19, 2016 ) Publisher's, 'Dystonia - Pipeline Review, H1 2016', provides an overview of the Dystonia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Dystonia
- The report reviews pipeline therapeutics for Dystonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dystonia therapeutics and enlists all their major and minor projects
- The report assesses Dystonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inquire before Purchasing Report @ http://www.reportsweb.com/inquiry&RW0001239356/buying
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dystonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001239356/sample
Table of Content: An Overview
Introduction 5
Publisher Report Coverage 5
Dystonia Overview 6
Therapeutics Development 7
Pipeline Products for Dystonia - Overview 7
Pipeline Products for Dystonia - Comparative Analysis 8
Dystonia - Therapeutics under Development by Companies 9
Dystonia - Therapeutics under Investigation by Universities/Institutes 11
Dystonia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Dystonia - Products under Development by Companies 15
Dystonia - Products under Investigation by Universities/Institutes 16
Dystonia - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
Advicenne Pharma 18
EpiVax, Inc. 19
Ipsen S.A. 20
Revance Therapeutics, Inc. 21
Dystonia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001239356/discount
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
abobotulinumtoxin A - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
abobotulinumtoxin A next generation - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dipraglurant ER - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
onabotulinumtoxin A - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RT-002 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
tetrabenazine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001239356/buy/2000
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|